SUNNYVALE, Calif., Aug. 18, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has appointed Shawn Cline Tomasello as its Chief Commercial Officer. Ms. Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4 billion in revenue. Prior to joining Celgene, Ms. Cline Tomasello was the National Director of Hematology for Rituxan® at Genentech, where she was responsible for over $1.7 billion in revenue.
"We are delighted to welcome Shawn in this important position," said Bob Duggan, Chairman & CEO, Pharmacyclics. "During her career, she has led commercial teams for two of the most successful global hematology products in the industry. Her exceptional and proven leadership skills and depth of experience within the hematology-oncology space will be tremendously valuable to the ongoing success and growth of IMBRUVICA® and to our company."
Ms. Cline Tomasello had been with Celgene since 2005, where she was responsible for all aspects of commercial sales and marketing for six brands encompassing 11 indications. In addition, she was instrumental in strategic decision making regarding global expansion and M&A evaluations which led to the acquisition and integration of Pharmion Corporation, Gloucester Pharmaceuticals, Inc. and Abraxis Biosciences, Inc.
Previously, Ms. Cline Tomasello was at Genentech for 16 years, where she was the National Director for Rituxan responsible for all in-line and new indications for the hematology commercial organization. At that time, Rituxan represented the majority of the company's corporate revenue. In addition, she held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble earlier in her career.
Ms. Cline Tomasello received her B.S. in marketing from the University of Cincinnati and her M.B.A. from Murray State University, KY.
About Pharmacyclics® Pharmacyclics, Inc. (NASDAQ: PCYC) is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The company's mission is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical needs. It will do so by identifying and controlling promising product candidates based on scientific development and administrative expertise, developing its products in a rapid, cost-efficient manner and, pursuing commercialization and/or development partners when and where appropriate.
Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and five preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to commercialization. Pharmacyclics is headquartered in Sunnyvale, CA. To learn more, visit www.pharmacyclics.com.
NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.
IMBRUVICA is a registered trademark of Pharmacyclics, Inc.
SOURCE Pharmacyclics, Inc.